Recombinant Human CLPS Protein，His

CLPS (Cationic Liposome-Protein Therapeutics System) is a novel platform in the field of protein therapeutics that focuses on improving the delivery and efficacy of recombinant proteins. The rising demand for effective biopharmaceuticals has driven research into innovative drug delivery systems that can enhance the stability, bioavailability, and targeted delivery of therapeutic proteins. Traditional methods often face challenges such as low solubility, rapid degradation, and non-specific distribution within the body. CLPS overcomes these limitations by utilizing cationic liposomes as carriers that encapsulate recombinant proteins and facilitate their transport to target tissues. This approach not only protects the proteins from enzymatic degradation but also enhances their cellular uptake through electrostatic interactions. The integration of CLPS with various therapeutic proteins, including antibodies and enzymes, has shown promising results in preclinical studies, demonstrating improved therapeutic efficacy and reduced side effects. As researchers continue to explore the potential of CLPS in various medical applications, including cancer therapy and gene delivery, it holds significant promise for advancing the field of personalized medicine and developing more effective treatments for a range of diseases.